Targeting the mechanisms of progression in castration-resistant prostate cancer.
نویسنده
چکیده
Until recently, few treatment options were available for metastatic castration-resistant prostate cancer (mCRPC). However, in recent years, there has been a rapid increase in the number of therapeutic options in addition to docetaxel. Novel therapies include the androgen synthesis inhibitor abiraterone, the antiandrogen enzalutamide, the taxane cabazitaxel, immunotherapeutic sipuleucel-T, and bonetargeting radium 223. Although these new therapies have shown an improvement in overall survival for patients with mCRPC, and although clinical trials optimising their sequence with one another may further increase survival values, death from mCRPC is invariably due to resistance to contemporary treatment modalities. Understanding the biology behind mCRPC is of crucial importance if we are to develop new and better treatment regimens for this patient group. In this month’s issue of European Urology, Karantanos et al provide an updated and in-depth review of issues pertaining to mechanisms behind development of resistance in mCRPC [1]. While the molecular basis implicated in the development of CRPC is complex and varied, it is clear that androgen receptor (AR) signalling remains an important driver of mCRPC despite systemic androgen deprivation and the new therapeutic options available today. Schweizer et al recently showed that docetaxel has only limited antitumor activity in CRPC patients previously treated with abiraterone [2], and this cross-resistance is likely due to interference of taxanes with the AR pathway [3]. Likewise, it has been reported that there is crossresistance between abiraterone and enzalutamide therapy, although a proportion of patients benefit from sequential treatment therapy [4]. Such resistance may be associated
منابع مشابه
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملSingle Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملSingle Orbital Metastasis in Castration-Resistant Prostate Cancer
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the...
متن کاملA profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a no...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- European urology
دوره 67 3 شماره
صفحات -
تاریخ انتشار 2015